Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iterum Therapeutics PLC

www.iterumtx.com

Latest From Iterum Therapeutics PLC

QIDP Roundup: Familiar Names Dominate 2019 Designations

US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.

Review Pathway Infectious Diseases

German Government Joins Superbug Fight With €40m CARB-X Investment

Germany’s Ministry of Education and Research has pledged €40m over four years to the antibacterial accelerator CARB-X, part of an overall €500m the country has committed to fighting superbugs in the next decade.

Infectious Diseases Germany

QIDP Program Heads Into Uncomplicated Territory: Iterum, Paratek Eye uUTI Indications

Iterum’ssulopenem is first QIDP candidate to enter Phase III for uncomplicated urinary tract infection; Paratek’sNuzyra could be next.

Review Pathway Clinical Trials

Pipeline Watch: Phase III Progress With BL-8040, Recorlev And Estelle

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Iterum Therapeutics Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Iterum Therapeutics PLC
  • Senior Management
  • Corey N Fishman, CEO
    Judith M Matthews, CFO
    Michael Dunne, MD, CSO
    Sailaja Puttagunta, MD, VP, Bus. Dev.
    Jeff Schaffnit, Chief Commercial Officer
  • Contact Info
  • Iterum Therapeutics PLC
    Phone: 1 903 8920
    Block 2 Fl. 3, Harcourt Centre
    Harcourt St.
    Dublin, 2
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register